Development PipelineSEA-CD40

an investigational sugar-engineered antibody directed to the immune-activating receptor CD40

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNS40-002: Melanoma and NSCLC (SEA-CD40 ± anti-PD1 ± chemotherapy)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGNS40-001: Advanced solid tumors and lymphomas (SEA-CD40 ± anti-PD1 ± chemotherapy)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SEA-CD40 and ongoing clinical trials

View/Download

Detailed information about SEA-CD40 clinical trials

View in Interactive Pipeline

Related Links

List of Congress
Presentations

Medical Information
Request Form

Back to Pipeline